Ruxolitinib and Lenalidomide As a Combination Therapy for Patients with Myelofibrosis

被引：0
|
作者：
Naval, Daver [1 ]
Cortes, Jorge E. [1 ]
Jabbour, Elias [1 ]
Pemmaraju, Naveen [1 ]
Jain, Nitin [1 ]
Estrov, Zeev [1 ]
Kornblau, Steven M. [1 ]
Burger, Jan A. [1 ]
Kantarjian, Hagop M. [1 ]
Newberry, Kate J. [1 ]
Verstovsek, Srdan [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis
    Daver, Naval
    Cortes, Jorge
    Newberry, Kate
    Jabbour, Elias
    Zhou, Lingsha
    Wang, Xuemei
    Pierce, Sherry
    Kadia, Tapan
    Sasaki, Koji
    Borthakur, Gautam
    Ravandi, Farhad
    Pemmaraju, Naveen
    Kantarjian, Hagop
    Verstovsek, Srdan
    HAEMATOLOGICA, 2015, 100 (08) : 1058 - 1063
  • [2] Pharmacoeconomics of ruxolitinib therapy in patients with myelofibrosis
    Vandewalle, Bjorn
    Andreozzi, Valeska
    Almeida, Joao
    Felix, Jorge
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (04) : 424 - 431
  • [3] PHARMACOECONOMICS OF RUXOLITINIB THERAPY IN PATIENTS WITH MYELOFIBROSIS
    Vandewalle, B.
    Andreozzi, V
    Almeida, J.
    Felix, J.
    VALUE IN HEALTH, 2015, 18 (07) : A456 - A456
  • [4] Combination therapy with pomalidomide and ruxolitinib in the treatment of myelofibrosis.
    Andrei, Mirela
    Sindhu, Hemant Singh
    Wang, Jan C.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis
    Gowin, K.
    Kosiorek, H.
    Dueck, A.
    Mascarenhas, J.
    Hoffman, R.
    Reeder, C.
    Camoriano, J.
    Tibes, R.
    Gano, K.
    Palmer, J.
    Mesa, R.
    LEUKEMIA RESEARCH, 2017, 60 : 31 - 35
  • [6] Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis
    Massimo Breccia
    Luigiana Luciano
    Novella Pugliese
    Elena Rossi
    Mario Tiribelli
    Emilia Scalzulli
    Massimiliano Bonifacio
    Bruno Martino
    Roberto Latagliata
    Giulia Benevolo
    Giovanni Caocci
    Gianni Binotto
    Vincenzo Martinelli
    Michele Cavo
    Fabrizio Pane
    Valerio De Stefano
    Robin Foà
    Francesca Palandri
    Annals of Hematology, 2019, 98 : 1933 - 1936
  • [7] A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis
    Masarova, Lucia
    Verstovsek, Srdan
    Hidalgo-Lopez, Juliana E.
    Pemmaraju, Naveen
    Bose, Prithviraj
    Estrov, Zeev
    Jabbour, Elias J.
    Ravandi-Kashani, Farhad
    Takahashi, Koichi
    Cortes, Jorge E.
    Ning, Jing
    Ohanian, Maro
    Alvarado, Yesid
    Zhou, Lingsha
    Pierce, Sherry
    Gergis, Romany
    Patel, Keyur P.
    Luthra, Rajyalakshmi
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Borthakur, Gautam
    Bhalla, Kapil
    Garcia-Manero, Guillermo
    Bueso-Ramos, Carlos E.
    Kantarjian, Hagop M.
    Daver, Naval
    BLOOD, 2018, 132 (16) : 1664 - 1674
  • [8] Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis
    Breccia, Massimo
    Luciano, Luigiana
    Pugliese, Novella
    Rossi, Elena
    Tiribelli, Mario
    Scalzulli, Emilia
    Bonifacio, Massimiliano
    Martino, Bruno
    Latagliata, Roberto
    Benevolo, Giulia
    Caocci, Giovanni
    Binotto, Gianni
    Martinelli, Vincenzo
    Cavo, Michele
    Pane, Fabrizio
    De Stefano, Valerio
    Foa, Robin
    Palandri, Francesca
    ANNALS OF HEMATOLOGY, 2019, 98 (08) : 1933 - 1936
  • [9] Ruxolitinib (RUX) in Combination with 5-Azacytidine (AZA) As Therapy for Patients (pts) with Myelofibrosis (MF)
    Daver, Naval
    Cortes, Jorge E.
    Pemmaraju, Naveen
    Jabbour, Elias J.
    Bose, Prithviraj
    Zhou, Lingsha
    Pierce, Sherry
    Van derbur, Stephanie
    Borthakur, Gautam
    Estrov, Zeev
    Garcia-Manero, Guillermo
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    BLOOD, 2016, 128 (22)
  • [10] RUXOLITINIB (RUX) IN COMBINATION WITH 5-AZACYTIDINE (AZA) AS THERAPY FOR PATIENTS (PTS) WITH MYELOFIBROSIS (MF)
    Daver, N.
    Cortes, J.
    Zhou, L.
    Pemmaraju, N.
    Jabbour, E.
    Borthakur, G.
    Estrov, Z.
    Garcia-Manero, G.
    Kantarjian, H.
    Verstovsek, S.
    HAEMATOLOGICA, 2015, 100 : 161 - 162
12345